Adicet Bio, Inc. Common Stock is the equity of Adicet Bio, a clinical-stage biotechnology company focused on developing allogeneic gamma delta T cell therapies for autoimmune diseases and cancer. The company’s current pipeline centers on engineered, off-the-shelf cell therapies designed to target specific disease markers through chimeric antigen receptors, with lead programs such as prulacabtagene leucel and ADI-212 addressing autoimmune and oncology indications. Adicet Bio’s research and development efforts are aimed at advancing differentiated cell therapy candidates that combine immune-cell engineering with tumor-targeting or disease-modifying mechanisms. The company operates within the biotechnology and health technology sectors, where its programs contribute to the broader development of next-generation immunotherapies for patients with serious and difficult-to-treat conditions. Adicet Bio is headquartered in Boston, Massachusetts.
Website131 Dartmouth Street
Boston, MA, 02116
United States
Adicet Bio (NASDAQ:ACET) reported 12-month DORIS remission in 54% of evaluable systemic lupus erythematosus patients and complete renal response in 50% of evaluable lupus nephritis patients, supporting plans to begin pivotal study start-up activities in the fourth quarter of 2026. Key Investor TakeawaysAdicet Bio (NASDAQ:ACET) reported positive prula-cel Phase 1 lupus data from 22 efficacy-evaluable patients, including 16 with lupus nephritis and six with extra-renal SLE.
The average of price targets set by Wall Street analysts indicates a potential upside of 258.2% in Adicet Bio (ACET). While the effectiveness of this highly sought-after metric is questionable, the positive trend in earnings estimate revisions might translate into an upside in the stock.
Here is how Adicet Bio, Inc. (ACET) and Centene (CNC) have performed compared to their sector so far this year.
Investors talking about ACET also mention
What share of all stock conversation is about ACET?
| 1 Day1D | 1 Week1W | 1 Month1M | 1 Year1Y | 50-Day MAclick to plot | 200-Day MAclick to plot | |
|---|---|---|---|---|---|---|
| Attention | 0% -0.01 | 0% +0 | 0% +0 | 0% 0 |
Of the messages about ACET that take a side, what share is each?
| 1 Day1D | 1 Week1W | 1 Month1M | 1 Year1Y | 50-Day MAclick to plot | 200-Day MAclick to plot | |
|---|---|---|---|---|---|---|
| Bullish | 66.67% +27.19 | 64.71% -35.29 | 61.9% -24.46 | 73.31% -15.23 | ||
| Bearish | 33.33% -27.19 | 35.29% +35.29 | 38.1% +24.46 | 26.69% +15.23 |
Of the messages about ACET that carry a topic, what share is each?
| 1 Day1D | 1 Week1W | 1 Month1M | 1 Year1Y | 50-Day MAclick to plot | 200-Day MAclick to plot | |
|---|---|---|---|---|---|---|
| Announcements | 66.67% | 86.84% | 92% | 86.71% | ||
| Technical Analysis | 0% | 0% | 0% | 3.96% | ||
| Analysts | 33.33% | 13.16% | 8% | 8.39% | ||
| Controversies | 0% | 0% | 0% | 0.16% | ||
| Earnings | 0% | 0% | 0% | 0.79% | ||
| Macro | 0% | 0% | 0% | 0% |
Of the messages about ACET, what share comes from each group?
| 1 Day1D | 1 Week1W | 1 Month1M | 1 Year1Y | 50-Day MAclick to plot | 200-Day MAclick to plot | |
|---|---|---|---|---|---|---|
| Regulars | 35.29% | 64.77% | 79.29% | 25.02% | ||
| Newcomers | 64.71% | 35.23% | 20.71% | 74.98% |